Find information on thousands of medical conditions and prescription drugs.

Fuzeon

Enfuvirtide, with trade name FuzeonĀ®, is a novel antiretroviral drug used in combination therapy for the treatment of HIV-1 infection. It is currently marketed by Hoffmann-La Roche under the trade name Fuzeon. more...

Home
Diseases
Medicines
A
B
C
D
E
F
Captagon
Famohexal
Famotidine
Faslodex
Faslodex
Fasoracetam
Felbamate
Felbatol
Felodipine
Felypressin
Femara
Femara
Fempatch
Femring
Fenfluramine
Fenofibrate
Fentanyl
Fexofenadine
Filgrastim
Filipin
Finasteride
Fioricet
Fiorinal
Flagyl
Flarex
Flavoxate
Flecainide
Flexeril
Flomax
Flonase
Flovent
Floxuridine
Fluacizine
Flucloxacillin
Fluconazole
Flucytosine
Fludarabine
Fludrocortisone
Flumazenil
Flunisolide
Flunitrazepam
Fluocinonide
Fluohexal
Fluorometholone
Fluorouracil
Fluoxetine
Fluphenazine
Flurazepam
Flutamide
Fluticasone
Fluvastatin
Fluvoxamine
FML
Focalin
Folic acid
Follutein
Fomepizole
Formoterol
Fortamet
Fortovase
Fosamax
Fosinopril
Fosinoprilat
Fosmidomycin
Fosphenytoin
Frova
Frovatriptan
Frusehexal
Fulvestrant
Fumagillin
Furazolidone
Furosemide
Furoxone
Fusafungine
Fusidic acid
Fuzeon
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Enfuvirtide is available only in injectable form since it is a peptide and would not survive digestion. The injections must be taken twice a day. This makes it inconvenient to take. With an estimated U.S. price of more than $25,000 for a year of Fuzeon, it is relatively expensive for an antiretroviral drug. Its inconvenience and price reserve it mostly for salvage therapy in patients with multi-drug resistant HIV.

The most common side effect is injection site reaction.

History

Trimeris Inc. began development on enfuvirtide in 1996 and initially designated it T-20. Trimeris partnered with Hoffmann-La Roche in 1999 to complete the drug's development. The medication has several disadvantages that resulted in its slow progress. It is difficult to manufacture, and is only available in an injectable form. The injections must be taken twice a day.

Its approval by the Food and Drug Administration (FDA) on March 13, 2003 made it the first of the new Fusion inhibitor class of antiretroviral drugs to be approved for use in the United States. It was approved on the basis of two studies (TORO 1 and TORO 2) which compared the effect of optimized regimens of antiretroviral medication with and without the addition of Fuzeon on serum viral load.

Mode of action

Enfuvirtide works by disrupting the HIV-1 molecular machinery at the final stage of fusion with the target cell, preventing uninfected cells from becoming infected. A biomimetic peptide, Enfuvirtide was rationally designed to mimic components of the HIV-1 fusion machinery and displace them, preventing normal fusion. Drugs that disrupt fusion of virus and target cell are termed entry inhibitors.


Greenberg, M. L. and N. Cammack (2004). "Resistance to enfuvirtide, the first HIV fusion inhibitor." J Antimicrob Chemother 54(2): 333-40.

Read more at Wikipedia.org


[List your site here Free!]



FDA approvals. for acromegaly treatment; enfuvirtide for HIV treatment - pegvisomant Somavert - Fuzeon
Pegvisomant. The U.S. Food and Drug Administration (FDA) has approved pegvisomant (Somavert) for the treatment of acromegaly in patients who have had an inadequate response to existing therapies.
New class of medications approved for advanced HIV - Updates - Fuzeon from Roche Pharmaceuticals
People infected with the virus that causes AIDS and who no longer respond to other treatments now have another option with approval of a new class of ...
New hope at an unprecedented price - Drugs - Food and Drug Administration approves Fuzeon - Brief Article
Hope and frustration marked the Food and Drug Administration's March 13 approval of Fuzeon--the first-ever drug to block HIV from entering human cells.
FDA approves Fuzeon drug has N.C. roots
Fuzeon[TM], the novel treatment for HIV-1 conceived by Trimeris (Nasdaq: TRMS) of Durham, and later co-developed with Roche of Nutley, N.J., was recently ...
Trimeris raises $102.4m, Fuzeon fast-tracked
Trimeris Inc. (Nasdaq: TRMS) of Durham recently raised about $102.4 million through a public offering of 2,400,000 shares of common stock. Net proceeds ...
T-20 gets priority review - FUZEON - Brief Article
On October 11 Roche and Trimeris, Inc. announced that the FDA had granted priority review to FUZEON (TM) (generic name enfuvirtide, formerly known as ...
Fuzeon NDA submitted
Trimeris Inc. (Nasdaq: TRMS) of Durham and development partner Roche of Nutley, N.J., recently submitted a New Drug Application (NDA) to the FDA for ...
Looking east for a new HIV drug
China's FusoGen Pharmaceuticals has developed a new HIV fusion inhibitor that is currently in human clinical trials. The drug has been registered as a new medicine with China's State Food and Drug A

Home Contact Resources Exchange Links ebay